Denali Therapeutics Inc. Common Stock DNLI
i
Market dataready · fetched 2026-11-11T14:21:42.865Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T14:21:13.493274313Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-11T14:21:42.500964+00:00
Denali Therapeutics Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 15.32 | 261.7% | 29.1% | |||
| 25Δ | 16.78 | 213.0% | 22.0% | |||
| 30Δ | 17.83 | 178.1% | 16.9% | |||
| 35Δ | 18.50 | 156.9% | 13.9% | |||
| 40Δ | 19.17 | 135.8% | 10.8% | |||
| 45Δ | 19.83 | 114.6% | 7.7% | |||
| 50Δ | 20.28 | 106.4% | 6.2% | |||
| 55Δ | 19.77 | 62.4% | 3.6% | 20.67 | 102.7% | 5.4% |
| 60Δ | 19.35 | 70.3% | 3.3% | 21.05 | 99.0% | 4.6% |
| 65Δ | 18.92 | 78.3% | 2.9% | 21.43 | 95.4% | 3.7% |
| 70Δ | 18.49 | 86.3% | 2.6% | 21.81 | 91.7% | 2.9% |
| 75Δ | 18.06 | 94.3% | 2.3% | 22.19 | 88.0% | 2.1% |
| 80Δ | 17.64 | 102.3% | 2.0% | 22.66 | 85.2% | 1.3% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 15.32
- IV
- 261.7%
- B/E move
- 29.1%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 16.78
- IV
- 213.0%
- B/E move
- 22.0%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 17.83
- IV
- 178.1%
- B/E move
- 16.9%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 18.50
- IV
- 156.9%
- B/E move
- 13.9%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 19.17
- IV
- 135.8%
- B/E move
- 10.8%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 19.83
- IV
- 114.6%
- B/E move
- 7.7%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 20.28
- IV
- 106.4%
- B/E move
- 6.2%
55Δ
- Pseudo strike
- 19.77
- IV
- 62.4%
- B/E move
- 3.6%
- Pseudo strike
- 20.67
- IV
- 102.7%
- B/E move
- 5.4%
60Δ
- Pseudo strike
- 19.35
- IV
- 70.3%
- B/E move
- 3.3%
- Pseudo strike
- 21.05
- IV
- 99.0%
- B/E move
- 4.6%
65Δ
- Pseudo strike
- 18.92
- IV
- 78.3%
- B/E move
- 2.9%
- Pseudo strike
- 21.43
- IV
- 95.4%
- B/E move
- 3.7%
70Δ
- Pseudo strike
- 18.49
- IV
- 86.3%
- B/E move
- 2.6%
- Pseudo strike
- 21.81
- IV
- 91.7%
- B/E move
- 2.9%
75Δ
- Pseudo strike
- 18.06
- IV
- 94.3%
- B/E move
- 2.3%
- Pseudo strike
- 22.19
- IV
- 88.0%
- B/E move
- 2.1%
80Δ
- Pseudo strike
- 17.64
- IV
- 102.3%
- B/E move
- 2.0%
- Pseudo strike
- 22.66
- IV
- 85.2%
- B/E move
- 1.3%
Options history
Table
| Date | IV (%) |
|---|---|
| 76.00% | |
| 74.62% | |
| 75.08% | |
| 75.23% | |
| 78.53% | |
| 84.63% | |
| 80.00% | |
| 77.65% | |
| 84.18% | |
| 80.24% |
Biotechnology
DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and…
More →DRTS
Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development, and commercialization of alpha-emitting radiation therapy (Alpha…
More →DRUG
Bright Minds Biosciences Inc. (DRUG) is a forward-thinking clinical-stage biotechnology firm specializing in the development of groundbreaking therapies for central nervous system…
More →DSGN
Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company is headquartered in Carlsbad,…
More →DTIL
Description unavailable
More →DYN
Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases in the United States. The…
More →